Initiation of intravitreal aflibercept injection treatment in patients with diabetic macular edema: a review of VIVID-DME and VISTA-DME data
暂无分享,去创建一个
[1] A. Yoshida,et al. SHORT-TERM EFFECT OF INTRAVITREAL RANIBIZUMAB THERAPY ON MACULAR EDEMA AFTER BRANCH RETINAL VEIN OCCLUSION , 2016, Retina.
[2] N. Bressler,et al. Aflibercept, Bevacizumab, or Ranibizumab for Diabetic Macular Edema: Two-Year Results from a Comparative Effectiveness Randomized Clinical Trial. , 2016, Ophthalmology.
[3] N. Bressler,et al. Five-Year Outcomes of Ranibizumab With Prompt or Deferred Laser Versus Laser or Triamcinolone Plus Deferred Ranibizumab for Diabetic Macular Edema. , 2016, American journal of ophthalmology.
[4] Jennifer K. Sun,et al. Association of Baseline Visual Acuity and Retinal Thickness With 1-Year Efficacy of Aflibercept, Bevacizumab, and Ranibizumab for Diabetic Macular Edema. , 2016, JAMA ophthalmology.
[5] Q. Nguyen,et al. Outcomes with As-Needed Ranibizumab after Initial Monthly Therapy: Long-Term Outcomes of the Phase III RIDE and RISE Trials. , 2015, Ophthalmology.
[6] P. Mitchell,et al. Three-year patient-reported visual function outcomes in diabetic macular edema managed with ranibizumab: the RESTORE extension study , 2015, Current medical research and opinion.
[7] P. Kaiser,et al. Intravitreal Aflibercept for Diabetic Macular Edema: 100-Week Results From the VISTA and VIVID Studies. , 2015, Ophthalmology.
[8] S. Sivaprasad,et al. Ranibizumab 0.5 mg for Diabetic Macular Edema with Bimonthly Monitoring after a Phase of Initial Treatment: 18-Month, Multicenter, Phase IIIB RELIGHT Study. , 2015, Ophthalmology.
[9] S. Wolf,et al. Prognostic significance of foveal capillary drop-out and previous panretinal photocoagulation for diabetic macular oedema treated with ranibizumab , 2015, British Journal of Ophthalmology.
[10] A. Koh,et al. The REVEAL Study: Ranibizumab Monotherapy or Combined with Laser versus Laser Monotherapy in Asian Patients with Diabetic Macular Edema. , 2015, Ophthalmology.
[11] J. Kleijnen,et al. Systematic review and mixed treatment comparison of intravitreal aflibercept with other therapies for diabetic macular edema (DME) , 2015, BMC Ophthalmology.
[12] Jennifer K. Sun,et al. Aflibercept, bevacizumab, or ranibizumab for diabetic macular edema. , 2015, The New England journal of medicine.
[13] P. Kaiser,et al. Intravitreal aflibercept for diabetic macular edema. , 2014, Ophthalmology.
[14] G. Virgili,et al. Anti-vascular endothelial growth factor for diabetic macular oedema. , 2014, The Cochrane database of systematic reviews.
[15] G. Lang,et al. Capacity of aflibercept to counteract VEGF-stimulated abnormal behavior of retinal microvascular endothelial cells. , 2014, Experimental eye research.
[16] P. Mitchell,et al. Three-year outcomes of individualized ranibizumab treatment in patients with diabetic macular edema: the RESTORE extension study. , 2014, Ophthalmology.
[17] A. Cruess,et al. Contemporary Management of Diabetic Retinopathy in Canada: From Guidelines to Algorithm Guidance , 2013, Ophthalmologica.
[18] N. Eter,et al. Stellungnahme der Deutschen Ophthalmologischen Gesellschaft, der Retinologischen Gesellschaft und des Berufsverbandes der Augenärzte Deutschlands: Therapie der diabetischen Makulopathie (Stand April 2013) , 2013, Klin Monatsbl Augenheilkd.
[19] Benjamin J. Thomas,et al. Evolving strategies in the management of diabetic macular edema: clinical trials and current management. , 2013, Canadian journal of ophthalmology. Journal canadien d'ophtalmologie.
[20] Ursula Schmidt-Erfurth,et al. One-year outcomes of the da Vinci Study of VEGF Trap-Eye in eyes with diabetic macular edema. , 2012, Ophthalmology.
[21] T. Peto,et al. A 2-year prospective randomized controlled trial of intravitreal bevacizumab or laser therapy (BOLT) in the management of diabetic macular edema: 24-month data: report 3. , 2012, Archives of ophthalmology.
[22] P. Mitchell,et al. New approaches for the treatment of diabetic macular oedema: recommendations by an expert panel , 2012, Eye.
[23] L. Aiello,et al. Rationale for the diabetic retinopathy clinical research network treatment protocol for center-involved diabetic macular edema. , 2011, Ophthalmology.
[24] E. Halm,et al. Predictors of adherence to diabetes medications: the role of disease and medication beliefs , 2009, Journal of Behavioral Medicine.
[25] Judy E. Kim,et al. Comparison of Aflibercept, Bevacizumab, and Ranibizumab for Treatment of Diabetic Macular Edema: Extrapolation of Data to Clinical Practice. , 2016, JAMA ophthalmology.
[26] N. Eter,et al. [Statement of the German Ophthalmological Society, the Retina Society and the Professional Association of German Ophthalmologists: treatment of diabetic maculopathy (April 2013)]. , 2013, Klinische Monatsblatter fur Augenheilkunde.